This week’s report covers Bayer’s prolonged sales slump, a price cut for self-pay Wegovy patients and much more.
This edition covers the implications of a jump in Medicare Part D spending on diabetes drugs, news that Madrigal Pharmaceuticals’ launch is going “exceptionally well” and much more.
This week’s edition covers BridgeBio’s fast launch, Pfizer’s continued pullback from gene therapies and the bargain basement buyout of bluebird bio.
This week’s edition covers Merck KGaA’s moves to buy a biotech, approvals for GSK, Roche and Pfizer and an update on the launch of Eisai and Biogen’s Leqembi.
The past week brought news of more cuts at Bristol Myers Squibb, quarterly earnings at companies including Eli Lilly, GSK and Pfizer and a legal row between Dupixent partners Regeneron and Sanofi.
The past week brought an early look at how political change may affect price negotiations, FDA approval of a Vertex drug that could deliver big blockbuster sales and much more.
The past week was rich with neuroscience news, with Johnson & Johnson reporting a jump in sales of its depression drug, Teva Pharmaceuticals receiving a black box safety warning for a multiple sclerosis treatment and much more.
J.P. Morgan Healthcare Conference week brought a flurry of news, including a $14.6 billion takeover by Johnson & Johnson and lackluster sales updates from Eli Lilly, Moderna and Regeneron.
This week brought analyses of drug pricing trends, predictions of another major market for GLP-1 drugs and much more.
Another batch of FDA approvals arrived over the new year period, bringing news of authorizations that could unlock Medicare coverage for Eli Lilly’s GLP-1 blockbuster Zepbound and open a new front in Bristol Myers Squibb’s long-running fight for the immuno-oncology market.
As the end of 2024 came into view, the FDA rattled off a series of authorization decisions, approving treatments from companies including Ionis Pharmaceuticals and Neurocrine Biosciences and rejecting applications from AstraZeneca, Johnson & Johnson and Zealand Pharma.
The past week delivered a bumper crop of late-phase cancer data as Eli Lilly, GSK, Johnson & Johnson, Pfizer and other drug developers used oncology events to share potentially practice-changing evidence on their products and prospects.
This week brought news of the winner of a head-to-head obesity trial, a meeting between pharma CEOs and the President-elect and much more.
Thanksgiving week brought updates on preparations for Donald Trump’s administration, Phase III wins for AstraZeneca and Merck and more.
This week brought updates on President-elect Donald Trump’s healthcare plans, rejections and approvals at the FDA and an increase in Novartis’ medium-term growth outlook.
Political events made the headlines over the past week as the incoming U.S. government began to take shape and drugmakers challenged resistance to new approaches to 340B rebates.
More earnings reports crossed the wires this week, shedding light on the evolving market for GLP-1 drugs and the competitive dynamics in other therapeutic areas.
This week brings a bumper crop of earnings news, with a setback to Eli Lilly contrasting with beat-and-raise quarters at multiple drugmakers including Pfizer.
This edition features updates on Pfizer’s row with an activist investor, the compounding of GLP-1 drugs and the potential availability and impact of a Eylea biosimilar.
Over the past week, Johnson & Johnson got pharma earnings season underway, the FDA delayed two regulatory decisions and AbbVie won approval at the third attempt.
This week’s report covers Bayer’s prolonged sales slump, a price cut for self-pay Wegovy patients and much more.
This edition covers the implications of a jump in Medicare Part D spending on diabetes drugs, news that Madrigal Pharmaceuticals’ launch is going “exceptionally well” and much more.
This week’s edition covers BridgeBio’s fast launch, Pfizer’s continued pullback from gene therapies and the bargain basement buyout of bluebird bio.
This week’s edition covers Merck KGaA’s moves to buy a biotech, approvals for GSK, Roche and Pfizer and an update on the launch of Eisai and Biogen’s Leqembi.